Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molec...
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve patient survival. Nevertheless, strategies to overcome intrinsic and acquired resistance are required to respectively increase response rates and durations. PD-L1 is often...
Alternative Titles
Full title
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2626890694
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2626890694
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/s41571-022-00601-9
